Dallas, TX (PRWEB) March 08, 2014
In-depth Research on China Animal Vaccine Industry, 2014 market report says the growth of China’s animal vaccine market was slowing down in 2013, it was estimated that year-on-year growth was about 15% and the market scale reached CNY 10.22 billion in 2013, of which, swine vaccine accounted for 50% shares and poultry vaccine accounted for 36%. At present, there are 88 animal vaccine manufacturers in China, with 338 production lines. But most of enterprises are small in scale, vaccine production inspection is not standard and product structures are not reasonable. Market shares are occupied by a minority of enterprises. Complete report is available at http://www.marketreportschina.com/in-depth-research-on-china-animal-vaccine-industry-2014.
According to the statistics by China Veterinary Drug Association (CVDA), the production capacity of live vaccines was 344.58 billion doses in 2012; the production capacity of inactivated vaccines was 55.392 billion milliliters; in China’s animal vaccine industry, the annual sales revenue reached CNY 8.888 billion in 2012, and the top 10 enterprises as for sales revenue accounted for 50% of total sales revenue of biological products.
Among the key animal vaccine manufacturers in China in 2012, China Animal Husbandry Industry Co., Ltd (CAHIC) obtained the most business income registering CNY 1.17 billion, accounting for 13.16% market share. TECON, Dahuanong, Jinyu Group and Ringpu also had more than 5% market share respectively.
Companies mentioned in In-depth Research on China Animal Vaccine Industry, 2014 report include China Animal Husbandry Industry Co., Ltd. (CAHIC), Qingdao Yebio Bioengineering Co., Ltd., Guangdong Dahuanong Animal Health Products Co. Ltd., TECON, Inner Mongolia Jinyu Group Stock Company, Tianjin Ringpu Bio-technology Co., Ltd. and Chengdu TECBOND Biological Products Co., Ltd. Order a copy of this report at http://www.marketreportschina.com/contacts/purchase?rname=4359.
Research and Forecast of China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2014-2018 is a market report that conducts in-depth analysis on the external environment, market operation, import & export of China’s IVD reagent industry, and also summaries the latest development of key Chinese domestic enterprises in 2013, and finally forecasts the future industrial development. The information can offer investors the decisive reference for their investment in the field. Complete report is available at http://www.marketreportschina.com/research-and-forecast-of-china-ivd-reagent-in-vitro-diagnostic-reagent-industry-2014-2018.
IVD reagent industry is an emerging industry in China, the start is late and the development is relatively backward compares with occidental countries. According to the data provided by IVD Special Committee, there are 300 to 400 IVD reagent manufacturing enterprises in China, of which, 200 enterprises own above designated scale. However, only about 20 enterprises have the ability to achieve annual sales income of more than CNY 100 million; most of enterprises are in small scale and the product variety is few.
In 2013, the market scale of China’s IVD industry reached CNY 22.5 billion; among them, the market scale of IVD reagents was about CNY 16.3 billion.
The state policy encourages the competitive enterprises to strengthen their strength. In 2013, a series of policies which target to improve industry standard and threshold entered the substantive operation stage, which accelerates the elimination of small enterprises and improves the industry concentration ratio. Industrial consolidation is the development trend, and the enterprises with capital, technology and scale advantages will win gradually.
In recent years, due to the continued sluggishness of European and American pharmaceutical market, the international giants target on the market expansion brought by China’s new medical reform, and entered China’s market in succession; after the China-oriented R&D center transfer, these powerful enterprises began to compete with China’s enterprises in the low and medium-end markets through mergers, acquisitions, capital increase and production expansion; therefore, the competitive enterprises in China’s diagnostic reagent subdivided industries will face more sever competitions.
Companies mentioned in Research and Forecast of China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2014-2018 report include Shanghai Kehua Bio-engineering Co., Ltd. , DAAN Gene Co., Ltd. , Shanghai Fosun Pharmaceutical (Group) CO., Ltd. , BioSino Bio-technology and Science Inc. , Beijing Leadman Biochemistry Co., Ltd. , Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Mindray and Zhejiang DIAN Diagnosis Co., Ltd. (DIAN Diagnosis). Order a copy of this report at http://www.marketreportschina.com/contacts/purchase?rname=4356.
Explore more reports on life sciences market in China at http://www.marketreportschina.com/category/life-sciences.
MarketReportsChina.com is an online database of global and Chinese industry research reports, for multiple industries and market segments. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Not limited to the Manufacturing industry, MarketReportsChina.com offers research studies on agriculture, retail, chemicals, consumer goods, environment, food and beverages, pharmaceuticals, agriculture, healthcare, advanced materials, medical devices, energy and power and much more.